摘要
目的 探索p5 3蛋白表达与DNA倍体、临床分期、病理分级及预后的关系。方法 采用流式细胞仪双参数检测了5 4例临床卵巢肿瘤手术标本的DNA含量和 p5 3蛋白表达。其中良性肿瘤 6例 ,卵巢癌 48例。同时采用免疫组化方法检测上述样本 2 0例的石蜡切片 ,观察 p5 3蛋白表达。 结果 经统计分析 ,采用免疫组化ABC法和流式细胞仪法检测的 p5 3蛋白表达者有明显一致性 (P <0 .0 1)。良、恶性肿瘤组织中 p5 3蛋白表达有显著性差异 (P <0 .0 5 ) ,p5 3蛋白高表达与异倍体明显相关 (P <0 .0 1) ,与临床分期也相关 (P <0 .0 5 )。p5 3蛋白阳性表达与阴性表达的生存率无显著性差异。 结论 p5 3蛋白高表达是 1个有意义的临床指标 ,但p5 3蛋白的高表达与预后无关。
Objective To explore the relationship between p53 protein expression,DNA ploidy and clinical characters in ovarian carcinoma and prognosis.Methods p53 protein expression and DNA content were examined in 54 samples obtained from 54 patients surgically treated(6 ovarian benign tumor;48 ovarian cancer) by bivariate flow cytometric analysis,p53 protein expression was also detected immunohistochemically in the same 20 cases in paraffin-embedded tissue.Results The results of two methods were correlated with each other in p53 protein expression( P <0.01).The frequency of p53-positive was associated with DNA index( P <0.01).The significant difference was observed in overexpression of p53 protein between clinical stage Ⅰ/Ⅱ and clinical stage Ⅲ/Ⅳ including metastasis and recurrence cancer.There was absence of correlation between p53 expression and prognostic factors.Conclusion The p53 expression is a significant clinical parameter,but it has no independent prognostic value in ovarian carcinoma.
出处
《实用癌症杂志》
2000年第5期505-507,共3页
The Practical Journal of Cancer
关键词
P53蛋白
DNA倍体
卵巢癌
预后
流式细胞仪
p53 expression
DNA ploidy
Ovarian carcinoma
Prognosis
Flow cytometric analysis